Open-source chemoinformatics platforms for multi-target structure-activity relationships
Source abstract
Abstract
Structure-activity relationships (SARs) are fundamental in medicinal chemistry, linking chemical structure with biological activity. However, many diseases involve multiple targets and pathways, making polypharmacology a key consideration. Traditional SAR approaches consider one target at a time, but the scale and complexity of modern screening data demand integrative methods. Chemoinformatic methods have been adapted to mine structure-multiple activity relationships (SMARTs) from large multi-target datasets, enabling analysis of compounds across multiple assays simultaneously. In this review, we map the current "SMART toolbox" of open-source chemoinformatics platforms, highlighting twelve tools that link chemical structures to diverse biological activities and provide integrative data-visualization capabilities. For each platform, we note open-source availability to promote reproducibility. Collectively, these platforms enable integrative visualization and analysis of multi-target activity landscapes, accelerating discovery of multi-functional therapeutics. Finally, we illustrate these approaches in a peptide design case study, showing how SMARTs analysis can guide the engineering of multi-functional bioactive compounds.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Computational Drug Discovery Methods · Protein Structure and Dynamics · Bioinformatics and Genomic Networks
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (66)
Show source-provided references
1. Bajorath · 2013
2. On exploring structure-activity relationships10.1007/978-1-62703-342-8_6 ↗
3. Network medicine: a network-based approach to human disease10.1038/nrg2918 ↗
4. The efficiency of multi-target drugs: the network approach might help drug design10.1016/j.tips.2005.02.007 ↗
5. Polypharmacology in precision oncology: Current applications and future prospects10.2174/1381612822666160923115828 ↗
6. Multitarget approaches against multiresistant superbugs10.1021/acsinfecdis.0c00001 ↗
7. Toward structure-multiple activity relationships (SMARts) using computational approaches: A polypharmacological perspective10.1016/j.drudis.2024.104046 ↗
8. Contributions of molecular properties to drug promiscuity: Miniperspective10.1021/jm301514n ↗
9. Polypharmacology: challenges and opportunities in drug discovery: Miniperspective10.1021/jm5006463 ↗
10. Network pharmacology: the next paradigm in drug discovery10.1038/nchembio.118 ↗
11. Computational multitarget drug design10.1021/acs.jcim.6b00491 ↗
12. Progress on open chemoinformatic tools for drug discovery
13. Progress on open chemoinformatic tools for expanding and exploring the chemical space10.1007/s10822-021-00399-1 ↗
14. Data structures and computational tools for the extraction of SAR information from large compound sets10.1016/j.drudis.2010.06.004 ↗
15. Web-based tools for polypharmacology prediction10.1007/978-1-4939-8891-4_15 ↗
16. Is the reductionist paradox an Achilles Heel of drug discovery?10.1007/s10822-022-00457-2 ↗
17. Chemprop v2: An efficient, modular machine learning package for chemical property prediction10.1021/acs.jcim.5c02332 ↗
18. Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii10.1038/s41589-023-01349-8 ↗
19. MAYA (Multiple ActivitY Analyzer): An open access tool to explore structure-multiple activity relationships in the chemical universe10.1002/minf.202400306 ↗
20. Web-based 3D-visualization of the DrugBank chemical space10.1186/s13321-016-0138-2 ↗
21. PubChem and ChEMBL beyond Lipinski
22. OpenChem: A deep learning toolkit for computational chemistry and drug design10.1021/acs.jcim.0c00971 ↗
23. DataWarrior: an open-source program for chemistry aware data visualization and analysis10.1021/ci500588j ↗
24. Monoamine oxidase inhibitors present in tobacco modulate dopamine balance via the dopamine transporter10.1021/acschemneuro.4c00789 ↗
25. Identification of potential aldose reductase inhibitors using convolutional neural network-based in silico screening10.1021/acs.jcim.3c00547 ↗
26. In silico end-to-end protein-ligand interaction characterization pipeline: The case of SARS-CoV-210.1021/acssynbio.1c00368 ↗
27. 3DSTarPred: A web server for target prediction of bioactive small molecules based on 3D shape similarity10.1021/acs.jcim.4c01445 ↗
28. SARANEA: a freely available program to mine structure-activity and structure-selectivity relationship information in compound data sets10.1021/ci900416a ↗
29. Enhancing hERG risk assessment with interpretable classificatory and regression models10.1021/acs.chemrestox.3c00400 ↗
30. Targeting Her2-insYVMA with covalent inhibitors-A focused compound screening and structure-based design approach10.1021/acs.jmedchem.0c00870 ↗
31. A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information10.1038/s41467-017-00680-8 ↗
32. De novo generation of multi-target compounds using deep generative chemistry10.1038/s41467-024-47120-y ↗
33. Deepmol: an automated machine and deep learning framework for computational chemistry10.1186/s13321-024-00937-7 ↗
34. From UK-2A to florylpicoxamid: Active learning to identify a mimic of a macrocyclic natural product10.1007/s10822-024-00555-3 ↗
35. Breaking free from chemical spreadsheets10.1016/j.drudis.2015.03.008 ↗
36. Pathfinder-driven chemical space exploration and multiparameter optimization in tandem with glide/IFD and QSAR-based active learning approach to prioritize design ideas for FEP+ calculations of SARS-CoV-2 PLpro inhibitors10.3390/molecules27238569 ↗
37. DeepautoQSAR hardware benchmark - Schrödinger
38. Scaffold hopping to imidazo[1,2-a]pyrazin-8-one positive allosteric modulators of metabotropic glutamate 2 receptor10.1021/acsomega.1c03739 ↗
39. Virtual screening in the cloud identifies potent and selective ROS1 kinase inhibitors10.1021/acs.jcim.2c00644 ↗
40. MAP4K4 inhibition promotes survival of human stem cell-derived cardiomyocytes and reduces infarct size in vivo10.1016/j.stem.2019.01.013 ↗
41. In silico anti-SARS-CoV-2 activities of five-membered heterocycle-substituted benzimidazoles10.1016/j.molstruc.2022.132869 ↗
42. Network analysis guided designing of multi-targeted anti-fungal agents: Synthesis and biological evaluation
43. Chemical space as a unifying theme for chemistry10.1186/s13321-025-00954-0 ↗
44. Getting SMARt in drug discovery: chemoinformatics approaches for mining structure–multiple activity relationships10.1039/C6RA26230A ↗
45. Identification of drug-target interactions via multiple information integration10.1016/j.ins.2017.08.045 ↗
46. Identification of drug candidates and repurposing opportunities through compound-target interaction networks10.1517/17460441.2015.1096926 ↗
47. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules10.1093/nar/gkz382 ↗
48. NetInfer: A web server for prediction of targets and therapeutic and adverse effects via network-based inference methods10.1021/acs.jcim.0c00291 ↗
49. Improving chemical similarity ensemble approach in target prediction10.1186/s13321-016-0130-x ↗
50. FastTargetPred: a program enabling the fast prediction of putative protein targets for input chemical databases10.1093/bioinformatics/btaa494 ↗
51. QSAR without borders10.1039/D0CS00098A ↗
52. A review of quantitative structure-activity relationship: The development and current status of data sets, molecular descriptors and mathematical models10.1016/j.chemolab.2024.105278 ↗
53. Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR10.1038/s41573-023-00832-0 ↗
54. The advancement of multidimensional QSAR for novel drug discovery - where are we headed?
55. QSAR multi-target in drug discovery: a review10.2174/157340991002140708105124 ↗
56. Machine learning in preclinical drug discovery10.1038/s41589-024-01679-1 ↗
57. Peptides from non-immune proteins target infections through antimicrobial and immunomodulatory properties10.1016/j.tibtech.2024.09.008 ↗
58. Deep learning reveals antibiotics in the archaeal proteome10.1038/s41564-025-02061-0 ↗
59. Discovery of antimicrobial peptides in the global microbiome with machine learning10.1016/j.cell.2024.05.013 ↗
60. Advanced delivery systems for peptide antibiotics10.1016/j.addr.2023.114733 ↗
61. A generative artificial intelligence approach for antibiotic optimization
62. Design of multimodal antibiotics against intracellular infections using deep learning
63. DBAASP v3: database of antimicrobial/cytotoxic activity and structure of peptides as a resource for development of new therapeutics10.1093/nar/gkaa991 ↗
64. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules10.1021/ci00057a005 ↗
65. One molecular fingerprint to rule them all: drugs, biomolecules, and the metabolome10.1186/s13321-020-00445-4 ↗
66. An overview of descriptors to capture protein properties - Tools and perspectives in the context of QSAR modeling10.1016/j.csbj.2023.05.022 ↗